Rationale and design of the LURIC study - A resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease

Pharmacogenomics

Volumn 2, Issue 1 SUPPL. 1, 2001, Pages

  Winkelmann, Bernhard R ^a   März, Winfried ^b   Boehm, Bernhard O ^c   Zotz, Rainer ^c   Hager, Jörg ^c   Hellstern, Peter ^c   Senges, Jochen ^c  

^a Heart Centre   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NONE

Author keywords

Cardiogenomics; Cardiovascular risk factor; Functional genomics; Genetic risk; Pharmacogenomics

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CELL SURFACE RECEPTOR; COTININE; CREATINE KINASE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DNA; FATTY ACID; GLUCOSE; GLYCEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUCLEOTIDE; ORAL ANTIDIABETIC AGENT; PHOSPHOLIPID; TRIACYLGLYCEROL; TROPONIN T; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANAMNESIS; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL IMMORTALIZATION; CLINICAL RESEARCH; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EXPOSURE; EXTRACTION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENETIC DISORDER; GENETIC RISK; GENETIC VARIABILITY; GERMANY; GLUCOSE TOLERANCE TEST; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INFORMED CONSENT; LEUKOCYTE; LIPID METABOLISM; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; METABOLISM; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATIENT SELECTION; PHARMACOGENOMICS; PHENOTYPE; POSTMENOPAUSE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PUBLIC HEALTH; QUALITY CONTROL; QUESTIONNAIRE; SMOKING; STROKE; THROMBOCYTE; CLASSIFICATION; GENETICS; GENOME; METHODOLOGY; PHARMACOGENETICS; REVIEW;

DIGITALIS;

CARDIOVASCULAR DISEASES; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; PROGNOSIS; RESEARCH DESIGN;

EID: 0034937299     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Epidemiology and prevention of coronary heart disease
2. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project - Registration procedures, event rates and case-fatality rates in 38 populations from 21 countries in four continents
3. Myocardial infarction community registers. Results of a WHO international collaborative study coordinated by the regional office for Europe
4. Unrecognized myocardial infarction: Five-year incidence, mortality and risk factors
5. Incidence and prevalence of recognised and unrecognised myocardial infarction in women
6. Prevalence, predisposing factors and prognosis of unrecognized myocardial infarction in the elderly
7. Unrecognized myocardial infarction and hypertension: The Framingham Study
8. A simple approximation for calculating sample sizes for comparing independent proportions
9. Estimating sample sizes for binary, ordered categorical and continuous outcomes in two group comparisons
10. Formulae for sample size, power and minimum detectable relative risk in medical studies
11. Sample size requirements in case-only designs to detect gene-environment interactions
12. Some thoughts on clinical trials, especially problems of multiplicity
13. Multiple testing of hypotheses in comparing two groups
14. Unstable angina - A classification
15. A reporting system on patients evaluated for coronary artery disease
16. The underlying coronary lesion in myocardial infarction: Implications for coronary angiography
17. Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries
18. Grading of angina pectoris
19. A classification of unstable angina revisited
20. The Selvester QRS scoring system for estimating infarct size: The development and application of the system
21. Q-wave versus non-Q-wave myocardial infarction: A meaningless distinction
22. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation
23. Pravastatin therapy and the risk of stroke
24. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart
25. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus - Provisional report of a WHO consultation
26. A survey of 246 suggested coronary risk factors
27. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis
28. Rapid apolipoprotein E phenotyping by immunofixation in agarose
29. Improvement of apolipoprotein E phenotyping by isoelectric focussing/immunofixation
30. A greatly simplified method of establishing B-lymphoblastoid cell lines
31. An efficient method for routine Epstein-Barr virus immortaliztion of human B lymphocytes
32. Histocompatibility testing by immunologic methods: Cellular assays
33. A desktop guide to Type 2 diabetes mellitus
34. Factors of risk in the development of coronary heart disease - Six-year follow-up experience. The Framingham Study
35. Sex and time trends in cardiovascular disease incidence and mortality: The Framingham Heart Study, 1950-1989
36. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The Procam experience and pathophysiological implications for reverse cholesterol transport
37. Identification of individuals at high risk for myocardial infarction
38. Atherosclerosis
39. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular in high-risk patiens
40. One-third of MI patients present to hospital without chest pain and are at increased risk for in-hospital mortality
41. Onset of Niddm occurs at least 4-7 yr before clinical diagnosis
42. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr
43. Genetic variation in coronary heart disease and myocardial infarction; methodological overview and clinical evidence
44. Genetics of coronary heart disease: Current knowledge and research principles
45. Role of gene polymorphisms in venous and arterial thrombotic disease
46. A simple approximation for calculating sample sizes for comparing independent groups